2023 Spring Seed Grant initiative in synergy with the Associations and Patients – Calls for Application

The 2023 Spring Seed Grant initiative in synergy with the Patient’s Associations is now open. The initiative aims at funding 12 months seed research projects with a maximum budget of 50,000 € (Lymphatic malformations Call; Mucopolysaccharidosis Type III or Sanfilippo Syndrome Call; UGDH or Jamuar syndrome Call; Neuronal Ceroid Lipofuscinosis or Batten disease Call; Polyglucosan body myopathy type 1 due to RBCK1 deficiency Call) and 18 months with a maximum budget of 70,000 € (PIGA deficiency or Multiple Congenital Anomalies Hypotonia-Seizures syndrome type 2 (MCAHS2) call).

These calls will give the opportunity to generate data and create new knowledge to pave the road for the development of new therapeutic approaches.

Italian investigators - working either in public or private Italian non-profit research Institutions, including Telethon Institutes - are eligible irrespectively of their funding status with Fondazione Telethon.

Applicants, even with active projects funded by FT, can apply and submit only one project within the 2023 Spring Seed Grant initiative, as Lead Applicant.

Agreements with Patient’s Associations have been reached for monothematic research calls on the following diseases:

The Calls, the Guidelines for the Applicants, the Application sample in .pdf format, the Reviewer’s guidelines, and the Management Rules document are available below and at the TeTra portal https://projects.telethon.it it is possible to access the online Application.

Deadlines

  • March 23rd, 2023: opening of calls for Applications.
  • by April 6th, 2023, applicants should:
    • register on the TeTra portal at https://projects.telethon.it
    • submit the project’s title
    • fill in the Type of Research section, providing the disease name and code, the Research Type and Research Step
  • April 28th, 2023 at 1 pm: submission deadline.

See specific calls documents :

Below you can download:

For more information, please send an email to:  [email protected].

Il tuo browser non è più supportato da Microsoft, esegui l'upgrade a Microsoft Edge per visualizzare il sito.